SCHEMBL30340772

SCHEMBL30340772

CCOC(=O)N1CCC(B2OC(C)(C)C(C)(C)O2)=C(C(=O)O)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.36
▸ MAPT P10636 6/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ GAA P10253 2/20 0.35
▸ SMN1; SMN2 Q16637 4/20 0.34
▸ GRM5 P41594 3/20 0.34
▸ LMNA P02545 2/20 0.34
▸ PABPC1 P11940 1/20 0.34
▸ ATM Q13315 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CACNA1C Q13936 1/20 0.34
▸ SCN5A Q14524 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ ALDH1A1 P00352 7/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ HPGD P15428 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30340769 0.90 TSHR (0.36) TSHRMAPTKDM4EGAASMN1; SMN2
SCHEMBL8252594 0.84 ADORA1 (0.42) MAPTKDM4ESMN1; SMN2LMNAALDH1A1
SCHEMBL4405414 0.82 TMEM97 (0.45) SMN1; SMN2GRM5CYP3A4CYP1A2MEN1
SCHEMBL1081654 0.82 ADORA1 (0.47) GAASMN1; SMN2LMNAATMALDH1A1
SCHEMBL2483591 0.75 ADORA1 (0.47) GAASMN1; SMN2LMNAATMALDH1A1
SCHEMBL17590014 0.72 UCHL1 (0.34) MAPTKDM4ECYP1A2MEN1KMT2A
SCHEMBL25305107 0.71 ESR2 (0.44) MAPTKDM4ESMN1; SMN2LMNARECQL
SCHEMBL2486254 0.71 MEN1 (0.48) MAPTKDM4ELMNACYP3A4ALDH1A1
SCHEMBL2483894 0.70 KDM4E (0.41) TSHRMAPTKDM4EGAASMN1; SMN2
SCHEMBL25315269 0.70 KDM4E (0.41) TSHRMAPTKDM4EGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12569485-B2 SMARCA inhibitors and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-03-10 — — US disclosed
US-20230103415-A1 SMARCA INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103415-A1 SMARCA INHIBITORS AND USES THEREOF SMARCC1, SMARCE1, SMARCA1 TSHR 4652/4885MAPT 3537/4885KDM4E 521/4885
US-12569485-B2 SMARCA inhibitors and uses thereof SMARCC1, SMARCC2, SMARCA2 TSHR 2550/4885MAPT 4757/4885KDM4E 1090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback